← Back to headlines
Leerink Upholds Outperform Rating for Crinetics Pharmaceuticals
Leerink has maintained its 'Outperform' rating for Crinetics Pharmaceuticals (CRNX), indicating a continued positive outlook for the company's stock.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
